1,781 Shares in The Clorox Company (NYSE:CLX) Purchased by GUNN & Co INVESTMENT MANAGEMENT INC.

GUNN & Co INVESTMENT MANAGEMENT INC. purchased a new stake in The Clorox Company (NYSE:CLX) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 1,781 shares of the company’s stock, valued at approximately $254,000.

Other hedge funds have also recently bought and sold shares of the company. Qube Research & Technologies Ltd increased its stake in shares of Clorox by 75.9% during the third quarter. Qube Research & Technologies Ltd now owns 1,130,481 shares of the company’s stock worth $148,161,000 after purchasing an additional 487,974 shares during the period. International Assets Investment Management LLC grew its holdings in Clorox by 17,658.5% in the 4th quarter. International Assets Investment Management LLC now owns 484,453 shares of the company’s stock valued at $69,078,000 after buying an additional 481,725 shares in the last quarter. Acadian Asset Management LLC increased its position in Clorox by 39.6% during the 3rd quarter. Acadian Asset Management LLC now owns 1,467,713 shares of the company’s stock worth $192,319,000 after buying an additional 415,999 shares during the period. FMR LLC lifted its holdings in shares of Clorox by 17.4% during the third quarter. FMR LLC now owns 2,415,054 shares of the company’s stock worth $316,517,000 after buying an additional 357,964 shares in the last quarter. Finally, Nuance Investments LLC boosted its position in shares of Clorox by 25.7% in the third quarter. Nuance Investments LLC now owns 1,325,789 shares of the company’s stock valued at $173,758,000 after acquiring an additional 271,133 shares during the period. 78.53% of the stock is currently owned by institutional investors and hedge funds.

Clorox Trading Up 0.8 %

Shares of CLX stock traded up $1.05 during mid-day trading on Monday, hitting $139.28. The company’s stock had a trading volume of 1,234,761 shares, compared to its average volume of 1,273,466. The company has a market cap of $17.30 billion, a PE ratio of 71.62, a P/E/G ratio of 2.13 and a beta of 0.44. The company has a debt-to-equity ratio of 9.73, a quick ratio of 0.53 and a current ratio of 0.90. The company’s fifty day simple moving average is $148.45 and its 200-day simple moving average is $143.43. The Clorox Company has a 52 week low of $114.68 and a 52 week high of $170.43.

Clorox (NYSE:CLX) last released its quarterly earnings data on Tuesday, April 30th. The company reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.33 by $0.38. Clorox had a net margin of 3.33% and a return on equity of 302.49%. The firm had revenue of $1.81 billion for the quarter, compared to analyst estimates of $1.87 billion. During the same period last year, the firm earned $1.51 earnings per share. The business’s quarterly revenue was down 5.3% compared to the same quarter last year. As a group, equities research analysts expect that The Clorox Company will post 5.83 earnings per share for the current fiscal year.

Clorox Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 10th. Investors of record on Wednesday, April 24th will be issued a $1.20 dividend. This represents a $4.80 annualized dividend and a yield of 3.45%. The ex-dividend date is Tuesday, April 23rd. Clorox’s dividend payout ratio (DPR) is currently 248.71%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on CLX shares. Wells Fargo & Company lowered their price target on shares of Clorox from $140.00 to $135.00 and set an “underweight” rating on the stock in a research report on Thursday. Citigroup lowered their target price on shares of Clorox from $155.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 1st. DA Davidson reiterated a “neutral” rating and issued a $162.00 price target on shares of Clorox in a research note on Wednesday, April 17th. The Goldman Sachs Group assumed coverage on Clorox in a research note on Friday, March 1st. They set a “sell” rating and a $140.00 price objective on the stock. Finally, Evercore ISI decreased their price target on Clorox from $145.00 to $142.00 and set an “underperform” rating on the stock in a research report on Wednesday, May 1st. Four equities research analysts have rated the stock with a sell rating and thirteen have given a hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $146.43.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.